Elizabeth A. Bayliss, MD, MSPH
Senior Investigator
Elizabeth A. Bayliss, MD, MSPH, is a Senior Investigator at the Institute for Health Research. Dr. Bayliss' research focuses on processes of care and methods for studying care delivery for patients and populations with complex care needs.
Dr. Bayliss completed her medical training at the University of Colorado Denver, where she also received her Master of Science in Public Health. She has served as Principal Investigator on studies of competing demands affecting individuals with complex care needs, developing quality measures for complex patients, assessing the impact of primary and specialty care continuity within an integrated delivery system, and improving medication prescribing practices for older adults with multiple chronic medical conditions.
Dr. Bayliss is a Professor of Family Medicine at the University of Colorado School of Medicine where she is a core faculty member for the the Primary Care Research Fellowship in health services research.
Selected Research:
- Generating Evidence on Deprescribing Safety (GEODES)
- Funder: National Institute on Aging
- Award End Date: 02/28/2025
- Optimal Medication Management in Alzheimer’s Disease and Dementia (OptiMIze)
- Funder: National Institute on Aging
- Award End Date: 01/31/2024
- Ethical Aspects of Physician Decision Making for Deprescribing
- Funder: National Institute on Aging
- Award End Date: 01/31/2024
- NIA AD/ADRD Health Care Systems Research Collaboratory
- Funder: National Institute on Aging
- Award End Date: 03/31/2024
- US Deprescribing Research Network
- Funder: National Institute on Aging
- Award End Date: 07/31/2024
This project aims to develop and test methods to generate evidence on deprescribing safety. It will address three fundamental methodological questions: Was a medication discontinued? If so, was there an adverse drug withdrawal event (ADWE)? And, which patients are at highest risk for ADWE from medication discontinuation?
With input from patients, care partners (family or friends who are involved in care), clinicians, and administrative stakeholders, we have developed a pragmatic deprescribing intervention to educate patients, care partners, and clinicians about deprescribing as one potential element of optimal medication management for ADRD-MCC patients. The intervention will target older adults with Alzheimer’s disease and related dementias (ADRD) with multiple chronic conditions and on 5 or more medications and their care partners in a pragmatic, cluster-randomized patientand care partner- centric deprescribing intervention to be conducted at KPCO.
This collaborative network will catalyze a range of research on deprescribing and search for solutions to improve the quality of pharmaceutical care and health outcomes for older adults.